Welcome!
Home Hyphens Pharma
Broker's Calls
Ardence Pharma deal favourable, analysts keep 'buy' on Hyphens Pharma
Although the incremental net profit contribution is likely negligible near term, the deal presents cross-selling opportunities.
October 23, 2023
Company in the news
Hyphens Pharma to acquire remaining 58% of shares in Ardence Pharma, making it a wholly-owned subsidiary
Hyphens Pharma sees the acquisition as a way to strengthen its Malaysian presence, first tranche worth $1.86 million.
October 17, 2023
Deals, joint ventures & alliances
Hyphens Pharma's DocMed partners Hoang Duc to digitalise pharmaceutical supply chain in Vietnam
Hyphens Pharma forms JV with Hoang Duc to digitalise Vietnam's pharmaceutical supply chain.
April 12, 2023
Company in the news
Hyphens Pharma licenses topical drug for acne across all Southeast Asia
Hyphens Pharma called the drug a “game-changer” for acne sufferers as it is so far the only topical cream to treat hormonal acne.
December 21, 2022
Broker's Calls
After record 3QFY2022, CGS-CIMB lifts TP, EPS and dividend forecasts on Hyphens Pharma
Hyphens Pharma reported an almost threefold y-o-y jump in its 3QFY2022 profit after tax to $4.0 million.
November 25, 2022
Results
Shares in Hyphens Pharma surge 11% as 3QFY2022 earnings see 270.8% jump
Shares in Hyphens Pharma have jumped some 10% in the morning following its stellar 3Q results.
November 10, 2022
Broker's Calls
PhillipCapital keeps ‘buy’ call on Hyphens Pharma as franchise expands with acquisitions
Hyphens Pharma’s revenue and patmi for the 1HFY2022 ended June stood at 54% and 67% of Chew’s FY2022 forecast respectively.
August 30, 2022
Broker's Calls
PhillipCapital upgrades Hyphens Pharma to 'buy' following $6 mil investment from Metro
Chew has raised FY2022 earnings by 40% to $9.2 million to incorporate earnings from the acquisition of Novem
June 07, 2022
Broker's Calls
Analysts positive on Hyphens Pharma as 1Q results beat expectations
CGS-CIMB gives a target price of 36 cents, while SAC Capital hands Hyphens a 40 cents target price.
May 20, 2022
Results
Hyphens Pharma reports 49.7% higher 1QFY2022 NPAT of $3.2 mil
Revenue increased by 18.5% y-o-y to $39.2 million thanks to contributions from its three business segments and Novem.
May 13, 2022